Nuvectis reports positive Phase 1b results for BRAF inhibitor NXP200 in glioma patients
Nuvectis Pharma presented expanded Phase 1b data for its oral BRAF inhibitor NXP200 at the 2026 ESMO Congress. The study of 27 patients with recurrent or progressive BRAF V600‑mutated gliomas showed an objective response rate of 40% in high‑grade and 42.9% in low‑grade disease, including four complete responses. The company said it will file a U.S. IND application for NXP200 by the end of 2026.
Why it matters
The company expects the IND filing to keep development on track, and the strong response rates could increase investor interest in the drug’s commercial potential. The share price fell 8.08% to $18.43 after the announcement, reflecting market reaction to the data and upcoming regulatory steps.
Key facts
- 1The Phase 1b study enrolled 27 patients, 20 with high‑grade glioma and seven with low‑grade glioma. rttnews.com
- 2Objective response rate was 40% in high‑grade glioma and 42.9% in low‑grade glioma. rttnews.com
- 3Four complete responses were observed, three in high‑grade and one in low‑grade disease. rttnews.com
- 4Tumor reduction occurred in 81.5% of patients and disease‑control rate reached 85.2%. rttnews.com
- 5Among safety‑evaluable patients, 14.3% experienced grade 3 or higher treatment‑related adverse events, with no discontinuations or deaths. rttnews.com
- 6Nuvectis plans to submit a U.S. IND application for NXP200 by year‑end 2026. rttnews.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.